Baidu
map

GUT: Alpha-1抗胰蛋白酶可控制小鼠和人类与酒精相关的肝病

2021-02-16 MedSci原创 MedSci原创

酒精相关性肝病(ALD)是全球性的医疗保健问题,治疗选择有限。在许多临床前和临床试验中,Alpha-1抗胰蛋白酶(AAT)显示出有强大的抗炎活性。

      酒精相关性肝病(ALD)是全球性的医疗保健问题,治疗选择有限。在许多临床前和临床试验中,Alpha-1抗胰蛋白酶(AAT)显示出有强大的抗炎活性。因此在这项研究中,研究人员旨在探讨AAT在ALD中的作用。

 

     

      研究人员对512名肝硬化患者进行了临床数据收集。比较了患有ALD和其他肝病病因的患者的生存时间,临床和生化参数,包括AAT血清浓度的差异。在实验性ALD模型中评估了AAT的作用,并进行了验证。

 

 

      研究结果显示AAT血清浓度低于120 mg / dL的肝硬化ALD患者与AAT血清浓度高于120 mg / dL的患者相比,死亡/肝移植的风险显着更高。多变量Cox回归分析表明,低AAT血清浓度是独立的生存时间影响因子。与配对喂养的小鼠相比,乙醇喂养的野生型(wt)小鼠肝脏AAT显着下降。为了测试AAT的治疗能力,将乙醇喂养的野生小鼠用人AAT治疗。AAT的给药改善了肝损伤,中性粒细胞浸润和脂肪变性。

       AAT浓度低于120 mg / dL的肝硬化ALD患者死亡/肝移植的风险增加。因此,AAT水平可以预测了人类ALD的治疗选择,尤其是酒精性肝炎的患者。

原始出处:

Christoph Grander. Et al. Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans. GUT. 2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2036020, encodeId=99f12036020ac, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Mon May 10 16:27:38 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779692, encodeId=c3341e79692b2, content=<a href='/topic/show?id=86c02348ce' target=_blank style='color:#2F92EE;'>#Alpha-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2348, encryptionId=86c02348ce, topicName=Alpha-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Jun 05 03:27:38 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945239, encodeId=3e6119452395c, content=<a href='/topic/show?id=249488e60fe' target=_blank style='color:#2F92EE;'>#蛋白酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88760, encryptionId=249488e60fe, topicName=蛋白酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Wed Jun 16 19:27:38 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048246, encodeId=9c2b204824649, content=<a href='/topic/show?id=20dc234e94' target=_blank style='color:#2F92EE;'>#Alpha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2347, encryptionId=20dc234e94, topicName=Alpha)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Tue Aug 17 02:27:38 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2021-05-10 jiekemin
  2. [GetPortalCommentsPageByObjectIdResponse(id=2036020, encodeId=99f12036020ac, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Mon May 10 16:27:38 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779692, encodeId=c3341e79692b2, content=<a href='/topic/show?id=86c02348ce' target=_blank style='color:#2F92EE;'>#Alpha-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2348, encryptionId=86c02348ce, topicName=Alpha-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Jun 05 03:27:38 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945239, encodeId=3e6119452395c, content=<a href='/topic/show?id=249488e60fe' target=_blank style='color:#2F92EE;'>#蛋白酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88760, encryptionId=249488e60fe, topicName=蛋白酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Wed Jun 16 19:27:38 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048246, encodeId=9c2b204824649, content=<a href='/topic/show?id=20dc234e94' target=_blank style='color:#2F92EE;'>#Alpha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2347, encryptionId=20dc234e94, topicName=Alpha)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Tue Aug 17 02:27:38 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2021-06-05 sunyl07
  3. [GetPortalCommentsPageByObjectIdResponse(id=2036020, encodeId=99f12036020ac, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Mon May 10 16:27:38 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779692, encodeId=c3341e79692b2, content=<a href='/topic/show?id=86c02348ce' target=_blank style='color:#2F92EE;'>#Alpha-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2348, encryptionId=86c02348ce, topicName=Alpha-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Jun 05 03:27:38 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945239, encodeId=3e6119452395c, content=<a href='/topic/show?id=249488e60fe' target=_blank style='color:#2F92EE;'>#蛋白酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88760, encryptionId=249488e60fe, topicName=蛋白酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Wed Jun 16 19:27:38 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048246, encodeId=9c2b204824649, content=<a href='/topic/show?id=20dc234e94' target=_blank style='color:#2F92EE;'>#Alpha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2347, encryptionId=20dc234e94, topicName=Alpha)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Tue Aug 17 02:27:38 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2021-06-16 canlab
  4. [GetPortalCommentsPageByObjectIdResponse(id=2036020, encodeId=99f12036020ac, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Mon May 10 16:27:38 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779692, encodeId=c3341e79692b2, content=<a href='/topic/show?id=86c02348ce' target=_blank style='color:#2F92EE;'>#Alpha-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2348, encryptionId=86c02348ce, topicName=Alpha-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Jun 05 03:27:38 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945239, encodeId=3e6119452395c, content=<a href='/topic/show?id=249488e60fe' target=_blank style='color:#2F92EE;'>#蛋白酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88760, encryptionId=249488e60fe, topicName=蛋白酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Wed Jun 16 19:27:38 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048246, encodeId=9c2b204824649, content=<a href='/topic/show?id=20dc234e94' target=_blank style='color:#2F92EE;'>#Alpha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2347, encryptionId=20dc234e94, topicName=Alpha)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Tue Aug 17 02:27:38 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2021-08-17 yhy100200

相关资讯

AJRCCM:PiZZ纯合子相关肺疾病患者常伴有慢性肝脏疾病

α1-抗胰蛋白酶缺乏症是人类最常见的遗传性疾病之一,该病患者容易出现肝脏和肺脏损害,其在基因表型表达方面的显著异质性,在文献中也已有很好的记载,但对于那些以肺部病变为主要表现的该病患者而言,其慢性肝病的患病率、严重程度、及其与肺部病变的相互关系等,则很少为人所知。为了明确在PiZZ纯合子相关肺疾病患者中,严重的肝纤维化、以及肝硬化的发生率及其危险因素,来自英国剑桥Addenbrooke医院组织病理

Blood:可用于治疗接触系统诱导的血栓炎症的α1-抗胰蛋白酶突变体

接触系统可产生炎症肽缓激肽,促进实验性血栓形成。C1酯酶抑制剂(C1INH)缺乏或XII因子 (FXII)功能获得性突变均可导致遗传性血管性水肿,一种危及生命的组织肿胀性疾病。C1INH是一种相对较弱的接触系统酶抑制剂。虽然α1-抗胰蛋白酶(α1AT)在自然情况下不能抑制酶接触系统,但人为给α1AT加一个突变(M358R;α1AT-Pittsburgh)即可将其改造成一种强大的广谱酶抑制剂。α1A

Baidu
map
Baidu
map
Baidu
map